Launch of our new TRICALS website

We are pleased to announce the official launch of our brand-new TRICALS website! Our new website provides up-to-date information about TRICALS and has many new features. 

What’s new?

We have reviewed all the existing information and added a range of new content to the website, such as:

  • you will easily find new information about upcoming clinical trials, such as the MAGNET platform trial.
  • We will now keep you updated about developments and achievements of TRICALS on our News page. So keep an eye on this webpage if you want to stay informed about the latest news or sign up for our newsletter.
  • In addition, on our new fundraising page you can read more about how you can help us in our mission. We now support the option to start your own fundraising campaign or you can donate to TRICALS directly. On our fundraising page you can read more about setting up your own campaign or you can take a look at existing ones.
  • We have also listed our future events for you on our Events page. Why not find out if we have anything planned near you?

So for now, take some time to explore our new website and we hope you like it as much as we do!


Share
Our upcoming trials
Recruiting
Phase iii

ALXN1210-ALS-308 trial

Industry trial
This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.
Read more
Recruiting
Phase iii

VALOR study

Industry trial
Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.
Read more
In preparation
Phase iii

The Lighthouse 2 trial

Investigator initiated trial
The Lighthouse 2 study is a phase 3 clinical trial in which we will investigate the efficacy of the drug Triumeq.
Read more
In preparation
Phase iii

MAGNET

Platform trial
MAGNET is an innovative clinical platform trial in which multiple treatments for ALS are investigated simultaneously.
Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more

Related news

The VALOR Study – A Clinical Trial for People Living with SOD1-ALS
The VALOR Study – A Clinical Trial for People Living with SOD1-ALS
Biogen is conducting a clinical trial to evaluate the safety and potential […]
Swimming the Catalan coast to raise funds for TRICALS
Swimming the Catalan coast to raise funds for TRICALS
To raise funds for TRICALS, Daniel Rossinés has taken on an epic […]
CENTAUR phase 2 trial reveals promising results
CENTAUR phase 2 trial reveals promising results
New findings from the CENTAUR trial show that the drug ‘sodium phenylbutyrate–taurursodiol’ […]
Current developments in clinical trial design and conduct
Current developments in clinical trial design and conduct
Over 70 compounds have been evaluated by clinical studies, yet Riluzole is […]